Pieris Pharmaceuticals, Inc. (PIRS) SEC Filing 8-K Material Event for the period ending Thursday, October 25, 2018

Pieris Pharmaceuticals, Inc.

CIK: 1583648 Ticker: PIRS

View differences made from one to another to evaluate Pieris Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pieris Pharmaceuticals, Inc..


Assess how Pieris Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Pieris Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Pieris Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: PIRS
CIK: 1583648
Form Type: 8-K Corporate News
Accession Number: 0001583648-18-000068
Submitted to the SEC: Thu Oct 25 2018 8:31:17 AM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Thursday, October 25, 2018
Industry: Commercial Physical And Biological Research
  1. Event for Officers
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: